Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 310

1.

Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo.

Freedman M, San Martin J, O'Gorman J, Eckert S, Lippman ME, Lo SC, Walls EL, Zeng J.

J Natl Cancer Inst. 2001 Jan 3;93(1):51-6.

2.

Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.

McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, Wang CY, Brunner RL, Johnson KC, Manson JE, Lewis CE, Kotchen JM, Hulka BS; Women's Health Initiative Mammogram Density Study Investigators.

J Natl Cancer Inst. 2005 Sep 21;97(18):1366-76.

3.

The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis.

Harvey JA, Holm MK, Ranganath R, Guse PA, Trott EA, Helzner E.

Menopause. 2009 Nov-Dec;16(6):1193-6. doi: 10.1097/gme.0b013e3181a7fb1e.

PMID:
19503006
4.

Postmenopausal hormone therapy and change in mammographic density.

Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G.

J Natl Cancer Inst. 2003 Jan 1;95(1):30-7.

5.

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.

Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG.

Breast Cancer Res Treat. 2001 Jan;65(2):125-34. Erratum in: Breast Cancer Res Treat 2001 May;67(2):191.

PMID:
11261828
6.

Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women.

Jackson VP, San Martin JA, Secrest RJ, McNabb M, Carranza-Lira S, Figueroa-Casas P, Fernandes CE, Romaguera J.

Am J Obstet Gynecol. 2003 Feb;188(2):389-94. Erratum in: Am J Obstet Gynecol. 2003 Jun;188(6):1628.

PMID:
12592245
7.

Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study.

Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, Panoulis KP, Kelekis DA, Creatsas GC.

Menopause. 2002 Mar-Apr;9(2):110-6.

PMID:
11875329
8.

Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.

Lippman ME, Krueger KA, Eckert S, Sashegyi A, Walls EL, Jamal S, Cauley JA, Cummings SR.

J Clin Oncol. 2001 Jun 15;19(12):3111-6. Erratum in: J Clin Oncol 2002 Mar 1;20(5):1430.

PMID:
11408508
9.

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR; CORE Investigators.

J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61.

10.

A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.

Reid IR, Eastell R, Fogelman I, Adachi JD, Rosen A, Netelenbos C, Watts NB, Seeman E, Ciaccia AV, Draper MW.

Arch Intern Med. 2004 Apr 26;164(8):871-9.

PMID:
15111373
11.

Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.

Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G.

Fertil Steril. 2009 Sep;92(3):1045-52. doi: 10.1016/j.fertnstert.2009.02.093. Epub 2009 Jul 26.

PMID:
19635616
12.

Effect of long-term treatment with raloxifene on mammary density in postmenopausal women.

Lasco A, Gaudio A, Morini E, Morabito N, Nicita-Mauro C, Catalano A, Denuzzo G, Sansotta C, Xourafa A, Macrì I, Frisina N.

Menopause. 2006 Sep-Oct;13(5):787-92.

PMID:
16912660
13.

Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.

Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, Bassett LW, Wasilauskas C, Bush T, Barrett-Connor E.

Ann Intern Med. 1999 Feb 16;130(4 Pt 1):262-9.

PMID:
10068383
14.

Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.

Mijatovic V, van der Mooren MJ, Kenemans P, de Valk-de Roo GW, Netelenbos C.

Menopause. 1999 Summer;6(2):134-7.

PMID:
10374220
15.

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.

Jolly EE, Bjarnason NH, Neven P, Plouffe L Jr, Johnston CC Jr, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW.

Menopause. 2003 Jul-Aug;10(4):337-44.

PMID:
12851517
16.

Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women.

Weinstein RS, Parfitt AM, Marcus R, Greenwald M, Crans G, Muchmore DB.

Osteoporos Int. 2003 Oct;14(10):814-22. Epub 2003 Aug 28.

PMID:
14610642
18.

Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.

Dias AR Jr, Melo RN, Gebara OC, D'Amico EA, Nussbacher A, Halbe HW, Pinotti JA.

Climacteric. 2005 Mar;8(1):63-70.

PMID:
15804733
19.

Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy.

Crandall CJ, Karlamangla A, Huang MH, Ursin G, Guan M, Greendale GA.

Arch Intern Med. 2006 Aug 14-28;166(15):1578-84. Erratum in: Arch Intern Med. 2006 Nov 13;166(20):2176.

PMID:
16908790
20.

Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method.

Eilertsen AL, Karssemeijer N, Skaane P, Qvigstad E, Sandset PM.

BJOG. 2008 May;115(6):773-9. doi: 10.1111/j.1471-0528.2008.01690.x. Epub 2008 Mar 19.

Items per page

Supplemental Content

Write to the Help Desk